Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Exploratory Study of INT-747 in Patients With Type 2 Diabetes Mellitus and Presumed Nonalcoholic Fatty Liver Disease

NCT00501592 is registered in ClinicalTrials.gov with Intercept Pharmaceuticals as lead sponsor.

NCT NCT00501592
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00501592 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Exploratory Study of INT-747 in Patients With Type 2 Diabetes Mellitus and Presumed Nonalcoholic Fatty Liver Disease
Lead sponsor
Intercept Pharmaceuticals
Phase
Phase 2
Overall status
Completed
Start date
July 31, 2007
Completion date
April 30, 2009
Enrollment
64 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

diabetes mellitus, type ii, fatty liver